The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

UMich buys Pfizer's Ann Arbor site

The University of Michigan announced that it will purchase Pfizer's Ann Arbor, MI plant for just $108 million--hundreds of millions less than what Pfizer has invested in the site over the years. It

Is Amgen worth $61B to Pfizer?

Yesterday, Deutsche Bank analyst Barbara Ryan proposed a Pfizer-Amgen combo, becoming the third industry watcher to float that particular trial balloon. Today, BNet's Jim Edwards asks, "why not?" If

Auxilium scores $485M pact with Pfizer

Auxilium Pharmaceuticals has scored a rich partnership pact with Pfizer for Xiaflex, a late-stage drug for the treatment of Dupuytren's contracture and Peyronie's disease. Malvern, PA-based Auxilium

Pfizer finds buyer for Cork plant

Portuguese contract manufacturer Hovione has purchased Pfizer's Cork, Ireland facility for an undisclosed sum. Pfizer has been trying to find a buyer for the site--which manufactures intermediates

Deutsche analyst: Pfizer likely to bid for Amgen

Noted Deutsche Bank analyst Barbara Ryan says that Pfizer is likely to make a major play to establish itself in biotechnology, with a bid for Amgen likely. Discussing the challenges that pharma

Surprise: Pfizer dividend flat, but Lilly's up

Call it a tale of two dividends. For the first time in 42 years, Pfizer is not hiking its quarterly dividend. Hardly shocking in today's economy and today's pharma industry, especially as the company

Pfizer slashes 700 jobs; Elan cuts 114

It's been a tough week of layoff talk in pharma, and today's even tougher. Not one, but two drugmakers announced job cuts: Pfizer and Elan. Pfizer is restructuring its operations in France, and you

Rumor mill: Pfizer making big R&D changes

What's up with Pfizer's R&D layoffs? The pharma giant announced last fall that it was restructuring its development work. And sources now tell Connecticut's The Day that the organizational

Pfizer jobs safe...through holidays

Pfizer's head of worldwide discovery research, Rod MacKenzie, communicated to employees that more research jobs will be on the chopping block, just as analysts predict ed, but he said he wouldn't be

Will Pfizer layoffs hit again in January?

Brace yourselves, Pfizer folks. Word is that another round of layoffs is on the way early next year. Industry analysts have been digging through the numbers, and they don't think the company has cut